Kailera reports Phase 1 data showing ribupatide injection exposure similar across abdomen, arm, thigh sites

By Public Technologies
  • Kailera highlighted Phase 1 ribupatide injection data already presented at EASD 2026.
  • Study supported flexible injection-site use, with comparable drug exposure across common sites.
  • Safety profile was broadly consistent across sites, with no new safety signals reported.
  • Separate Phase 1 results presented by partner Hengrui showed KAI-4729 delivered strong weight-loss signals with tolerability consistent with GLP-1 therapies.
  • Kailera plans to start a Phase 1 KAI-4729 trial outside China in 2026, with data expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010645PRIMZONEFULLFEED9837440) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.